[HTML][HTML] Veliparib in combination with platinum-based chemotherapy for first-line treatment of advanced squamous cell lung cancer: a randomized, multicenter phase …
SS Ramalingam, S Novello, SZ Guclu… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
SS Ramalingam, S Novello, SZ Guclu, D Bentsion, Z Zvirbule, M Szilasi, R Bernabe…
Journal of Clinical Oncology, 2021•ncbi.nlm.nih.govPURPOSE Squamous non–small-cell lung cancer (sqNSCLC) is genetically complex with
evidence of DNA damage. This phase III study investigated the efficacy and safety of poly
(ADP-ribose) polymerase inhibitor veliparib in combination with conventional chemotherapy
for advanced sqNSCLC (NCT02106546
evidence of DNA damage. This phase III study investigated the efficacy and safety of poly
(ADP-ribose) polymerase inhibitor veliparib in combination with conventional chemotherapy
for advanced sqNSCLC (NCT02106546
Abstract
PURPOSE
Squamous non–small-cell lung cancer (sqNSCLC) is genetically complex with evidence of DNA damage. This phase III study investigated the efficacy and safety of poly (ADP-ribose) polymerase inhibitor veliparib in combination with conventional chemotherapy for advanced sqNSCLC (NCT02106546
ncbi.nlm.nih.gov
